Impact of adherence to pharmacotherapy in rheumatic diseases
Authors:
Zb. Hrnčíř
Authors‘ workplace:
II. interní gastroenterologická klinika LF UK a FN, Hradec Králové
Published in:
Čes. Revmatol., 29, 2021, No. 2, p. 107-113.
Category:
Overview
Adherence to therapy is a primary determinant of treatment success. Poor adherence atenuates optimum clinical benefits and therefore reduces the overal effectivness of health systems. According to the World Health Organization, risk factors/predictors for nonadherence may be categorized based on five interacting dimensions: socioeconomic, health-care system-related, disease-related, therapy-related, and patient-related. Nonadherence to pharmacotherapy may include non-acceptance of drug prescription start, poor execution of the drug regimen, discontinuation and the drug prescription end. Databases on adherence to pharmacotherapy in rheumatic diseases include a large amount of prospective and retrospective studies with variable methods of investigation, i.e. from questionaries and detection the presence of drugs or metabolites in biologic fluids up to sophisticated electronic telemetry. A data are suggestive that nonadherence to pharmacotherapy should be a risk factor even to fatal prognosis, incl. nonadherence in relation to placebo. In this connection a characteristics of nonadherence syndrome were declared. In rheumatic diseases were analysed especially data as follows: disease modyfying anti-rheumatic drug therapy in rheumatoid arthritis, glucocorticoids in polymyalgia rheumatica, hydroxychloroquine and immunosuppressive therapy in systemic lupus erythematosus and uric acid blockers in gout. A good information on poor adherence to pharmacotherapy of rheumatic diseases suppose successful education of patients in the whole clinical practice.
Keywords:
adherence to pharmacotherapy – nonadherence syndrome – rheumatoid arthritis – polymyalgia rheumatica – systemic lupus erythematosus – gout
Sources
- World Health Organization. Adherence to long-term therapies: evidence for action. Reference No 2003; 110. www.wno.int/hiv/pub/prev-care/lttherapies/en/
- Šedová L. Tomasová Studýnková J. Doporučení České revmatologické společnosti 2020 k perioperační úpravě léčby zánětlivých revmatických onemocnění. Čes. Revmatol. 2020; 28: 5–15.
- Šenolt L. Stanovisko České revmatologické společnosti k léčbě revmatických onemocnění a očkování v kontextu infekce SARSCoV-2. Čes. Revmatol. 2020; 28: 197–205.
- Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Diseases in Adult Patients during the COVID-19 pandemic:version 3. Arthritis Rheumatol. 2021; 73: el-e12. doi 10.1002/art.41596
- Simpson SH, Eurich DT, Majumdar SR, Padwal ES, Tauyuju RT. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333(7557): 15. doi:10.1136/bmj.38875.675486.55
- Reach G, Chenuc G, Maigret P, Elias-Billon I, Martinez L, Flipo RM. Implication of character trials in adherence to treatment in people with gout: a reason for considering nonadherence as a syndrome. Patient Preference and Adherence 2019; 13: 1913–1926.
- Feldman CH, Costenbader KH, Solomon DH, Subramanian SV, Kawachi I. Area-level predictors of medication nonadherence among US medicaid beneficiaries with lupus: A multilevel study. Arthritis Care Res 2019; 71: 903–913.
- Mirabel M, Ferreira B, Sidi D, Lachaud M, Jouven X, Marijan E. Rhumatisme articulaire aigu: perspectives. Med Sci (Paris) 2012; 28: 633–638.
- Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with Methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol 2016; 43: 1997–2009.
- Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Meging Veterans Affairs rheumatoid registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res 2011; 63: 1680–1690.
- Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatsidionysiou K, Dougalos M, et al. EULAR recommendation for the management of rheumatoid arthritis with sythetic and biological disease-modyfying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960–977.
- McDougall JA, Ferucci ED, Glover J, Fraenkel L. Telerheumatology: A Systematic review. Arthritis Care Res 2017; 69: 1546–1557.
- Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol 2011; 64: 255–257.
- Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open 2019; 5: e 000585.
- Vogelzang EH, Hebing RCF, Nurmohamed MT, van Kuijk AWR, Kruijff JWF, I Ami MJ, et al. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS ONE 2018; 13(10): e020515.
- Waimann ChA, Marengo MF, de Achaval S, Cox VL, Carcia-Gonzales A, Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disavantaged patients with rheumatoid arthritis. Arthritis Rheumat 2013; 65: 1421–1429.
- Petri M, Elkhalifa M, Li J, Madger LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 2020; 72: 448–453.
- Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheumat 2006; 54: 2550–2557.
- Feldman CN, Collins J, Zhang Z, YU Ch, Subramanian SV, Kawachi I, Solomon DH. Azathioprine and mycophenolate mofetil adherence and predictors among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res 2019; 72: 1419–1424.
- Ntatsaki E, Vassiliou VA, Velo-Garcia A, Salama AD, Isenberg DA. Renal transplantation for lupus nephritis: non-adherence and graft survival. Lupus 2019; 28: 651–657.
- Mehat P, Atiquzzman M, Esdaile JM, Aviňa-Zubieta A, de Vera MA. Medication nonahderence in systemic lupus erythematosus: A systematic review. Arthritis Care Res 2017; 69: 1706–1713.
- Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival. Arthritis Rheumat 2010; 62: 855–862.
- Yin R, Li L, Zhang G, Cui Y, Zhang L, Zhang Q, et al. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. BMJ Open 2018; e017542.
- DeVera Ma, Macrotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: A systematic review. Arthritis Care Res 2014; 66: 1551–1559.
- Emamifar A, Gildberg-Mortensen R, Just SA, Lomborg N, Amundsen Andersen R, Jensen Hansen IM. Level of adherence to prophylactic osteoporosis medication amongst patients with polymyalgia rheumatica and giant cell arteritis: A cross-sectional study. Int J Rheumatol 2015; e783709
- Horák P. Nedostatek vitaminu D a jeho zdravotní dopady. Vnitř. Lék 2019; 65: 724–727.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2021 Issue 2
Most read in this issue
- NOVÁ DOPORUČENÍ PRO PACIENTY s dnou a zvýšenou hladinou kyseliny močové v krvi
- Nová doporučení pro léčbu lupusové nefritidy
- Overview of biomarkers and their relationship to axial spondyloarthritis associated with idiopathic inflammatory bowel diseases
- Doporučení České revmatologické společnosti pro farmakologickou léčbu axiálních spondyloartritid